Ariceum Therapeutics
Dr. Carol Andrea Pregonero Gamez has a diverse work experience in the field of project management and clinical research. CAROL ANDREA started their career as a Graduate Research Assistant at the Biomedical Engineering Department of MSU in 2005 and worked there until 2009. From 2011 to 2014, they worked at Theradex Europe as a Clinical Research Associate and later as a Senior CRA/Junior PM. CAROL ANDREA then joined Centro Investigacion Clinica CIC-CCBR as a Clinical Operations Manager from February 2015 to December 2015.
In 2016, Dr. Pregonero Gamez joined Covance as a Regional CRA II and worked there until February 2018. CAROL ANDREA then took on the role of a Senior CRA II at Covance in April 2019, where they worked until 2022.
In 2022, they moved to Theragnostics and worked as a Project Manager until 2023. Currently, they are working as a Project Manager at Ariceum Therapeutics, starting in June 2023.
Throughout their career, Dr. Pregonero Gamez has gained expertise in project management, clinical operations, and clinical research.
Carol Andrea Pregonero Gamez, PhD has a strong educational background in biomedical engineering and cardiovascular research. CAROL ANDREA completed their Doctor of Philosophy (PhD) in Biomedical Engineering with a specialization in Cardiovascular Research at Mississippi State University. Prior to their doctoral studies, they obtained a Bachelor's degree in Biomedical/Medical Engineering from Escuela de Ingeniería de Antioquia.
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.